1 / 12

IFF for Immunziation Andrew Jones Senior Programme Officer, Innovative Financing

Learn about the GAVI Alliance and the IFFIm, a large-scale funding mechanism to double global aid for vaccines. Discover how the IFFIm leverages donor commitments in the bond market to accelerate immunization efforts and lower vaccine prices.

carmelaa
Download Presentation

IFF for Immunziation Andrew Jones Senior Programme Officer, Innovative Financing

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IFF for ImmunziationAndrew JonesSenior Programme Officer, Innovative Financing 0

  2. GHP: The GAVI Alliance • The PPP model • Works through and using partners’ comparative advantages • Quick learning and driver for innovation • Coordinationand consensus building amongpartners • Around policies, strategies and priorities related to vaccines and immunisation 1

  3. The GAVI Alliance 2

  4. The IFF • Need for predictable long-term resources- not just more – but better aid • The IFF has been conceived as a large-scale US$50 billion per year mechanism to double global aid and help meet the MDGs • An IFF for immunization (IFFIm) has been proposed as a pilot for the IFF mechanism 3

  5. The IFFIm • On September 9th, 2005 the IFFIm was launched in London with the five donors - UK, France, Italy, Spain, and Sweden: now Norway and Brazil have announced contribution as well • Estimated disbursable of $3.2 billion before 2015 • Ongoing effort to secure resources from additional donors to reach $4 billion resource goal • Target date for first bond issuance is September 2006 4

  6. Components of the IFFIm • Donors enter into 20 year legally binding commitments • These commitments are leveraged in the bond market • Proceeds distributed to countries and for supply procurement • Resources nominally split 50/50 systems and vaccines 5

  7. The IFF: Donor Pledges Long term commitments generate near term resources Disbursements (to programs) Pledges from Donors Spare cash – “cushion” 6

  8. Offers of DTP + HepB Vaccine to UNICEF For both WHO prequalified & non-prequalified vaccines 12 $1.20 Weighted average price Weighted average price 10 $1.00 $0.80 8 Number of Manufacturers Price per Dose $0.60 6 $0.40 4 $0.20 2 $0 2001 2002 2003 2004 2005 2006 The IFFIm: Speeding Availability Predictable, long-term flows can accelerate market forces GAVI’s significant resources have stimulated the entry of additional manufacturers for combination vaccines, resulting in a price drop ultimately delivering more vaccines to children 7

  9. The IFFIm: Leverage in Market IFFIm funds could lower prices more rapidly Price per dose Source: CGD Working Paper “The costs and benefits of front-loading and predictability of immunization” 8

  10. Implications of the IFFIm • New donors • Countries not previously contributing to GAVI attracted by innovative nature of IFFIm supplying additional resources • Influencing the market • Long-term predictable commitments allow longer-term planning for supply strategy • More flexibility for contracts with manufacturers with a potential to negotiate a lower price or accelerate supply through strategic use of long-term contracting • Better planning and sustainability for countries • Commitments can be made to countries over longer-term allowing for better integration within national planning cycles and longer lead time to plan for country financing and eventual sustainablility 9

  11. Cost vs. Benefit Additional IFFIm impact IFFIm Funds Continued growth of current funding Continued gains in lives saved due to growth of current funding The IFFIm raises additional monies through a borrowing mechanism (securitization)….. …but saves many additional lives more quickly. 10

  12. Cost vs. Benefit • Principal IFFIm benefits are: • Accelerating coverage of immunisation with traditional and new and under used vaccines, and • ‘pulling’ the vaccine industry through predictable market, leading to increased industry capacity and lower vaccine prices • Key benefits are 5.3 million additional children’s lives saved over 10 years, ( Africa 3.1 million, Asia 2.1 million and others 0.1 million) • A further 5 million adult lives saved through HepB • Estimated “financial cost” of IFFIm at 3.5% against IRR of accelerated benefits of 18% 11

More Related